OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx is viewed favorably because its healthcare point-of-care network reaches more than 2M HCPs and 240M patients, while DAAP and Micro-Neighborhood Targeting deepen its shift toward a higher-margin, data-driven platform embedded in the clinical workflow. Despite 2Q26 revenue falling 30% year over year to $20.5M, EBITDA margin expanded to 24.1% and gross margin reached 76.5%, showing that management is protecting profitability as legacy managed services wind down and the business resets around a smaller base. The improved balance sheet, including a May 2026 refinancing at about 6.5%, $8.3M of debt paydowns, and a net cash position of $5.1M, together with DeepIntent’s May 2026 integration as a third-party programmatic supply source, gives the company a credible path to stronger 2027 execution.

OptimizeRx is facing a structurally fragile revenue base, with three customers each contributing over 10% of 2025 revenue and roughly 62% of sales routed through just two channel partners, leaving margins and growth exposed to partner leverage and customer churn. TTM revenue per top 20 pharma manufacturer fell 14% year over year to $2.7M, NRR dropped from 110% in 1Q to 90% in 2Q, and management has already acknowledged execution missteps that helped lose a major customer relationship. Policy and operating risks further cloud the outlook, as MFN pricing actions, IRA-related drug price pressure, and a shift away from lower-margin managed services could disrupt pharma marketing budgets, create near-term revenue volatility, and constrain the company’s ability to offset declining legacy demand.